Free Trial
NYSE:PBH

Prestige Consumer Healthcare Q4 2026 Earnings Report

Prestige Consumer Healthcare logo
$55.54 -0.21 (-0.37%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Prestige Consumer Healthcare EPS Results

Actual EPS
N/A
Consensus EPS
$1.39
Beat/Miss
N/A
One Year Ago EPS
N/A

Prestige Consumer Healthcare Revenue Results

Actual Revenue
N/A
Expected Revenue
$293.76 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prestige Consumer Healthcare Announcement Details

Quarter
Q4 2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Prestige Consumer Healthcare Earnings Headlines

Premium Brands: I Waited A Year For This Dip
SMX: Where Physical Energy Meets Digital Truth
SMX (Security Matters) PLC is embedding invisible, tamper-proof molecular signatures into crude oil, refined fuels, and petrochemical products — turning every barrel into a verifiable, traceable digital asset. In volatile energy markets where margins can vanish overnight, SMX gives producers, refiners, and traders real-time visibility across the supply chain while delivering instant emissions and compliance data to regulators.tc pixel
See More Prestige Consumer Healthcare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prestige Consumer Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prestige Consumer Healthcare and other key companies, straight to your email.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare (NYSE:PBH), Inc. is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy). Prestige distributes its products primarily in the United States and Canada through supermarket, drug store, mass merchandise, dollar, club and e-commerce channels, and selectively in other markets through export partnerships.

Formed through a series of strategic acquisitions of established consumer healthcare names, Prestige Consumer Healthcare has grown by integrating well-known OTC brands under a centralized commercial and operational platform. The company is headquartered in Tarrytown, New York, and leverages a focused R&D and regulatory support team to drive incremental innovation across its brand portfolio. Tony Long has served as President and Chief Executive Officer since December 2019, leading initiatives to expand Prestige’s market presence and enhance its category leadership.

View Prestige Consumer Healthcare Profile